Login

WORKSHOP “PHYSICS FOR HEALTH IN EUROPE”

2–4 Feb 2010
CERN
Europe/Zurich timezone

Support

Session

Session 2: Radioisotopes in diagnostics and therapy

3 Feb 2010, 08:30
500/1-001 - Main Auditorium (CERN)

500/1-001 - Main Auditorium

CERN

400
Show room on map

Description

Chair: Jean- Francois Chatal (ARRONAX), Rapporteur: Ulli Koester (ILL)

Presentation materials

There are no materials yet.

  1. 155. Keynote:'Radioisotopes in diagnostics and therapy, (pre-)clinical view
    Otto Boerman, W.J.G Oyen (Radbout University Nijmegen Medical Centre)
    03/02/2010, 08:30
  2. 29. Production of innovative radionuclides at ARRONAX and 211At RIT
    Dr F. HADDAD (GIP ARRONAX and SUBATECH, Nantes)
    03/02/2010, 09:00
    Radioisotopes in diagnostics and therapy
    Oral presentations
    ARRONAX, acronym for "Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantique", is a high energy and high intensity cyclotron. It will turn into operation in the beginning of 2010 in Nantes (France). It is mainly devoted to the production of radionuclides for medicine. A priority list based on the capability of the machine as well as on the need expressed by the European...
    Go to contribution page
  3. 101. Tb-149 radio-immunotherapy - advances of short-range alpha radiation and 4.1 h half-life demonstrated in vitro and in vivo
    Dr Matthias Miederer (Universitätsmedizin Mainz, Germany)
    03/02/2010, 09:10
    Radioisotopes in diagnostics and therapy
    Oral presentations
    Radioimmunotherapy (RIT) of disseminated diseases in which individual cells or cell clusters are remaining requires a radionuclide that is capable of sterilizing individual cells with minimal radiotoxicity to surrounding healthy tissue. α particles exhibit high linear energy transfer and very short range in tissue, making them ideal for single-cell killing. 149Tb is a radiolanthanide that...
    Go to contribution page
  4. 82. Radiation Protection Aspects Related to Lutetium-177 Use in Hospitals
    Dr Richard Henkelmann (Isotope Technologies Garching)
    03/02/2010, 09:20
    Radioisotopes in diagnostics and therapy
    Oral presentations
    177Lu is typically produced by direct irradiation with neutrons from enriched 176Lu. During direct irradiation of 176Lu remarkable amount of 177mLu (T1/2 = 160 d) is produced. The 177mLu content in the labelling solution is mainly depending from the two factors: irradiation time and how much time has passed after end of the irradiation. Typically carrier added (c.a.) 177Lu is produced in...
    Go to contribution page
  5. 92. Preclinical studies with non-standard and carrier-free radioisotopes from ISOLDE-CERN
    Gerd Beyer (Department of Radiology)
    03/02/2010, 09:30
    Radioisotopes in diagnostics and therapy
    Oral presentations
    Systemic radionuclide therapy is a very challenging field of nuclear medicine. The search of new tracers that may become a radiopharmaceutical is driven mainly by disciplines as biochemistry, organic chemistry and coordination chemistry, while modern radiochemical or nuclear physics achievements are often not adequately included. Frequently the development of new radiopharmaceuticals is...
    Go to contribution page
  6. 160. Discussion on therapy including possible use of ISOLDE isotopes
    03/02/2010, 09:40
  7. 161. Keynote: ' Production of radioisotopes for medical applications'
    N. Ramamoorthy (IAEA Vienna)
    03/02/2010, 10:30
  8. 162. Panel discussion on 99mTc supply crisis and alternatives with short contributions followed by interactive discussion
    03/02/2010, 10:55
  9. 54. The Future for 99mTc and 99Mo in nuclear medicine
    Prof. Dewi M. Lewis (General Electric Healthcare)
    03/02/2010, 10:55
    Radioisotopes in diagnostics and therapy
    Oral presentations
    The Future for 99mTc and 99Mo in nuclear medicine 99mTc is an unusual radionuclide choice for imaging but has become the most frequently used radioisotope in nuclear medicine and has made single photon emission computed tomography (SPECT) an extremely powerful in-vivo diagnostic imaging tool. Recent advances in imaging camera technology offer a very promising future for this method of...
    Go to contribution page
  10. 47. Feasibility study of an accelerator-driven production of Mo-99 for Tc-99m generators using a high-power LINAC
    Mr luca maciocco (advanced accelerator applications)
    03/02/2010, 11:15
    Radioisotopes in diagnostics and therapy
    Oral presentations
    Feasibility study of an accelerator-driven production of Mo-99 for Tc-99m generators using a high-power LINAC A compact accelerator-driven neutron activator based on a modified version of the Adiabatic Resonance Crossing (ARC) concept, proposed by C. Rubbia and experimentally demonstrated at CERN in 1997, has been developed with the aim of efficiently exploiting ion-beam generated neutrons...
    Go to contribution page
  11. 86. Gallium-68 – a candidate for use in clinical routine
    Dr Mark Harfensteller (ITG Isotope Technologies Garching, Germany)
    03/02/2010, 11:35
    Radioisotopes in diagnostics and therapy
    Oral presentations
    The 68Ge/68Ga radionuclide generator (68Ge, T1/2 = 270.95 d) is an excellent cyclotron-independent source for the positron emitter 68Ga which is successfully used in clinical PET. Nevertheless there remain open problems in the routine use related to the applicability of the technique in clinical environment and legal aspects. An effective application of the generator produced 68Ga can be...
    Go to contribution page
Building timetable...